2016
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Semrad T, Redman M, Herbst R, Kim E, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Hirsch F, Kelly K, Gandara D. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 9082-9082. DOI: 10.1200/jco.2016.34.15_suppl.9082.Peer-Reviewed Original Research
2005
O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib
Eberhard D, Johnson B, Goddard A, Herbst R, Janne P, Johnson D, Klein P, Ostland M, Seshagiri S, Hillan K. O-186 Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib. Lung Cancer 2005, 49: s62. DOI: 10.1016/s0169-5002(05)80320-4.Peer-Reviewed Original ResearchPreliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1 st -line treatment in patients with NSCLC
Johnson B, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, Heymach J. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1 st -line treatment in patients with NSCLC. Journal Of Clinical Oncology 2005, 23: 7102-7102. DOI: 10.1200/jco.2005.23.16_suppl.7102.Peer-Reviewed Original ResearchA randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Blumenschein G, Khuri F, Gatzemeier U, Miller W, von Pawel J, Rigas J, Herbst R, Dziewanowska Z, Negro-Vilar A, Mabry M. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2005, 23: lba7001-lba7001. DOI: 10.1200/jco.2005.23.16_suppl.lba7001.Peer-Reviewed Original Research
2004
159 Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel
Wu W, Shintani T, O'Reilly M, Herbst R. 159 Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel. European Journal Of Cancer Supplements 2004, 2: 50-51. DOI: 10.1016/s1359-6349(04)80167-8.Peer-Reviewed Original ResearchPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.14_suppl.2050.Peer-Reviewed Original ResearchPharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)
Tran H, Zinner R, Blumenschein G, Oh Y, Papadimitrakopoulou V, Kim E, Lu C, Malik M, Lum B, Herbst R. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC). Journal Of Clinical Oncology 2004, 22: 2050-2050. DOI: 10.1200/jco.2004.22.90140.2050.Peer-Reviewed Original Research
2000
Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
Khuri F, Glisson B, Meyers M, Herbst R, Thall P, Munden R, Bangert S, Cascino M, Shin D, Kurie J, Papadimitrakopoulou V, Fossella F, Pisters K, Hong W. Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety. Lung Cancer 2000, 29: 63-64. DOI: 10.1016/s0169-5002(00)80205-6.Peer-Reviewed Original Research